Investigation of Genetic Risk of Atrial Fibrillation

The recruitment status of this study is unknown because the information has not been verified recently.
Verified December 2006 by Nagoya University.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
Nagoya University
ClinicalTrials.gov Identifier:
NCT00412438
First received: December 15, 2006
Last updated: NA
Last verified: December 2006
History: No changes posted
  Purpose

The atrial fibrillation (AF) is the most common cardiac rhythm disturbance that is responsible for substantial morbidity and mortality independent of associated heart disease or other risk factors. Even in the absence of preexisting cardiovascular disease, AF remains significantly associated with excess mortality rates. The current unsatisfactory treatment for AF comes from lack of understanding of the pathophysiology of AF. The purpose of this study is to identify gene polymorphisms that confer susceptibility to atrial fibrillation. Patients with AF(N=500) and healthy volunteer(N=1000) without AF are enrolled in this study. Patients with coronary artery disease, severe valvular heart disease, cardiomyopathy or heart failure were excluded from the study.


Condition
Atrial Fibrillation

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Cross-Sectional
Official Title: Investigation of Genetic Risk of Atrial Fibrillation

Resource links provided by NLM:


Further study details as provided by Nagoya University:

Estimated Enrollment: 1000
Study Start Date: October 2006
  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Clinical diagnosis of atrial fibirillation

Exclusion Criteria:

  • coronary artery disease
  • severe valvular heart disease
  • cardiomyopathy
  • heart failure
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00412438

Contacts
Contact: Kenji Yasui, MD, PhD +81-52-788-6211 kenji@riem.nagoya-u.ac.jp
Contact: Masaki Yamauchi, MD +81-52-788-6210 g030744d@mbox.nagoya-u.ac.jp

Locations
Japan
Department of Bio-information Analysis, Research Institute of Enviromental Medicine, Nagoya University Recruiting
Nagoya, Aichi, Japan
Contact: Kenji Yasui, MD, PhD    +81-52-6211    kenji@riem.nagoya-u.ac.jp   
Contact: Masaki Yamauchi, MD    +81-52-6211    g030744d@mbox.nagoya-u.ac.jp   
Sponsors and Collaborators
Nagoya University
Investigators
Study Chair: Kenji Yasui, MD, Phd Department of Bio-information Analysis, Research Institute of Enviromental Medicine, Nagoya University
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00412438     History of Changes
Other Study ID Numbers: RIEM-G-1
Study First Received: December 15, 2006
Last Updated: December 15, 2006
Health Authority: Japan: Ministry of Education, Culture, Sports, Science and Technology

Keywords provided by Nagoya University:
Atrial Fibrillation

Additional relevant MeSH terms:
Atrial Fibrillation
Arrhythmias, Cardiac
Heart Diseases
Cardiovascular Diseases
Pathologic Processes

ClinicalTrials.gov processed this record on August 18, 2014